Stamford Advocate– Purdue Pharma is facing questions from a Congressional committee investigating the opioid crisis, opening another round of scrutiny for the embattled maker of OxyContin.
Robert Bird
Beleaguered Purdue Pharma Makes Leadership Changes
Purdue Pharma Faces Private-Sector Litigation
With Less Than 80 Days to Regulatory Deadline, Neo4j Urges Organizations to Turn GDPR Compliance Into Strategic Advantage
PR Newswire– In lead-up to GDPR’s looming May 25, 2018 deadline, Neo4j, the market leader in connected data, is urging any company that is investing in GDPR compliance to use those investments for a long-term, strategic advantage. As part of that effort, Neo4j is offering an interactive, personalized demonstration and solution assessment, which shows organizations how to use connected data to meet GDPR compliance, and also how to turn those compliance investments into a strategic advantage.
U.S. Seeks Repayment from Purdue Pharma
Senate Report Probes Purdue Pharma Donations to Nonprofits
Purdue Faces Uphill Battle to Overcome Opioid Controversy
New York’s Suit Against Purdue Pharma Could Have Major Impact
Stamford Advocate– New York City this week added a new dimension to the legal crisis facing Purdue Pharma.
The nation’s largest city is suing several pharmaceutical firms including Stamford’s Purdue, one of the most prominent of the many lawsuits that blame the company for fueling the opioid crisis.
Purdue Pharma, Prosecutors Continue Dialogue
Stamford Advocate – As a growing number of states pursue legal action against Purdue Pharma for allegedly stoking the nation’s opioid crisis, both sides are seeking to avoid protracted and costly cases.
UConn Alum Malfettone Speaks About Corporate Compliance as a Competitive Advantage
John Malfettone ’77, senior managing director and chief compliance officer at Clayton, Dubilier, and Rice, spoke to 100 students and alumni about “Corporate Compliance as a Competitive Advantage.” Continue Reading